Interview with Carlos de Sousa, CEO of Immunicum
28 Mar 2017 08:436700
Carlos de Sousa explains the uniqueness and potential of Intuvax, what to expect during the next 12 months and why Immunicum is an attractive investment opportunity.
Read more
Carlos de Sousa explains the uniqueness and potential of Intuvax, what to expect during the next 12 months and why Immunicum is an attractive investment opportunity.
Viewers had the opportunity to ask questions in an interesting Q&A session after Carlos de Sousa, CEO of Immunicum, presented corporate developments and financial results. The discussion also included Klas Palin, Life Science analyst, and Chief Editor, Eddie Palmgren.
This page is using cookies to help give you the best experience possible.
Okay, then I know!Read more